These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1451 related articles for article (PubMed ID: 20065329)

  • 1. Three decades of beta-lactamase inhibitors.
    Drawz SM; Bonomo RA
    Clin Microbiol Rev; 2010 Jan; 23(1):160-201. PubMed ID: 20065329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].
    Susić E
    Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.
    Lister PD
    Pharmacotherapy; 2000 Sep; 20(9 Pt 2):213S-218S; discussion 224S-228S. PubMed ID: 11001328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-lactamases and beta-lactamase inhibitors.
    Williams JD
    Int J Antimicrob Agents; 1999 Aug; 12 Suppl 1():S3-7; discussion S26-7. PubMed ID: 10526867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational and data mining studies to understand the distribution and dynamics of Temoneria (TEM) β-lactamase and their interaction with β-lactam and β-lactamase inhibitors.
    Gehlot P; P H
    Environ Pollut; 2022 Dec; 314():120289. PubMed ID: 36180000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination beta-lactam and beta-lactamase-inhibitor products: antimicrobial activity and efficiency of enzyme inhibition.
    Rotschafer JC; Ostergaard BE
    Am J Health Syst Pharm; 1995 Mar; 52(6 Suppl 2):S15-22. PubMed ID: 7606585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tackling the Antibiotic Resistance Caused by Class A
    Eiamphungporn W; Schaduangrat N; Malik AA; Nantasenamat C
    Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30061509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations.
    Thomson KS; Weber DA; Sanders CC; Sanders WE
    Antimicrob Agents Chemother; 1990 Apr; 34(4):622-7. PubMed ID: 2344169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular basis of antibiotic resistance and beta-lactamase inhibition by mechanism-based inactivators: perspectives and future directions.
    Therrien C; Levesque RC
    FEMS Microbiol Rev; 2000 Jul; 24(3):251-62. PubMed ID: 10841972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors of β-Lactamases. New Life of β-Lactam Antibiotics.
    Egorov AM; Ulyashova MM; Rubtsova MY
    Biochemistry (Mosc); 2020 Nov; 85(11):1292-1309. PubMed ID: 33280574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of beta-lactamase-mediated antimicrobial resistance: the role of beta-lactamase inhibitors.
    Maddux MS
    Pharmacotherapy; 1991; 11(2 ( Pt 2)):40S-50S. PubMed ID: 2041831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. β-lactam antibiotics: An overview from a medicinal chemistry perspective.
    Lima LM; Silva BNMD; Barbosa G; Barreiro EJ
    Eur J Med Chem; 2020 Dec; 208():112829. PubMed ID: 33002736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolutionary Trajectories toward High-Level β-Lactam/β-Lactamase Inhibitor Resistance in the Presence of Multiple β-Lactamases.
    Rajer F; Allander L; Karlsson PA; Sandegren L
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0029022. PubMed ID: 35652643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New promising β-lactamase inhibitors for clinical use.
    Olsen I
    Eur J Clin Microbiol Infect Dis; 2015 Jul; 34(7):1303-8. PubMed ID: 25864193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclic Boronates Inhibit All Classes of β-Lactamases.
    Cahill ST; Cain R; Wang DY; Lohans CT; Wareham DW; Oswin HP; Mohammed J; Spencer J; Fishwick CW; McDonough MA; Schofield CJ; Brem J
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28115348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
    Qadri SM; Ueno Y; Cunha BA
    Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
    Bonomo RA; Rudin SA; Shlaes DM
    FEMS Microbiol Lett; 1997 Mar; 148(1):59-62. PubMed ID: 9066111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-lactamase-mediated resistance and opportunities for its control.
    Livermore DM
    J Antimicrob Chemother; 1998 Jun; 41 Suppl D():25-41. PubMed ID: 9688449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to beta-lactam antibiotics: structure and mechanism based design of beta-lactamase inhibitors.
    Sandanayaka VP; Prashad AS
    Curr Med Chem; 2002 Jun; 9(12):1145-65. PubMed ID: 12052169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of beta-lactamase inhibitors.
    Rolinson GN
    Surg Gynecol Obstet; 1991; 172 Suppl():11-6. PubMed ID: 2024221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 73.